Follow us for updates
© 2022
Read the Story →

Searching for COVID-19 Treatment, Clinical Trials Start for Japan's Avigan

Two other possible cures are being tested.
by Joel Guinto
Aug 4, 2020
Photo/s: Agence France-Presse

The Philippines started clinical trials for Japanese anti-flu drug Avigan to determine if it could help treat COVID-19 patients, Japan's news wire Kyodo reported. This will widen potential treatments for the disease that has infected over 100,000 Filipinos and plunged a quarter of the population in a fresh lockdown.

Clinical trials are also underway for anti-Ebola drug remdesivir and the anti-viral interferon, according to the report. These are different from upcoming clinical trials for a COVID-19 vaccine, for which the Philippines is pursuing several possible sources. President Rodrigo Duterte earlier said that with China's help, a vaccine could be available by the end of the year and would be free for 20 million people.

More from reportrworld

Health Usec. Rosario Vergeire did not immediately return a text message from reportr seeking comment on the Kyodo report. Last week, she said the Philippines received some 199,000 Avigan tablets for the clinical trials. Manufactured by Japan's Fujifilm Holdings Corp, Avigan has the generic name favipiravir.

Continue reading below ↓

Metro Manila, Bulacan, Rizal, Laguna and Cavite were on Monday placed under Modified Enhanced Community Quarantine, the second strictest in the country's four-step classification system. It will last until Aug. 18, during which the government will recalibrate its pandemic fighting strategy.

Continue reading below ↓
Recommended Videos

It took a distress call from health frontliners over the weekend for Duterte to restore the MECQ. Doctors, nurses and hospital workers warned that fast-rising cases risked overwhelming the system. 

Latest Headlines
Read Next
Recent News
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.